Laura M Lyall1, Nagore Penades2, Daniel J Smith3. 1. Research Associate,Institute of Health and Wellbeing, University of Glasgow,UK. 2. Consultant in General Adult Psychiatry,National Health Service Greater Glasgow and Clyde,UK. 3. Professor of Psychiatry,Institute of Health and Wellbeing, University of Glasgow,UK.
Abstract
BACKGROUND: People with bipolar disorder typically require long-term pharmacological treatment to prevent episodes of depression or mania. However, evidence-based guidelines are often not followed by prescribers and, in some countries, prescribing of lithium is in decline. Polypharmacy is also common in bipolar disorder.AimsTo employ a data linkage approach to describe and evaluate prescribing patterns in bipolar disorder in Scotland between 2009 and 2016. METHOD: By linking prescribing data to the electronic Scottish Morbidity Records, we identified a cohort of 23 135 patients with bipolar disorder who were prescribed psychotropic medication between 2009 and 2016. We examined trends in proportions of patients prescribed each of six drug categories. Random effects logistic models examined change in prescribing over years of interest. RESULTS: The most common form of treatment was antidepressant monotherapy (24.96%), with only 5.90% of patients receiving lithium monotherapy. Prescribing of antipsychotics and anti-epileptics increased from 2009 to 2016 (antipsychotics: odds ratio 1.16, 95% CI 1.15-1.18; anti-epileptics: odds ratio 1.34, 95% CI 1.32-1.36), whereas prescribing of lithium decreased (odds ratio 0.83, 95% CI 0.82-0.85). Prescribing of valproate decreased from 2009-2016 in women, but increased in men (women: odds ratio 0.93, 95% CI 0.90-0.97; men: odds ratio 1.11, 95% CI 1.04-1.18). CONCLUSIONS: Antidepressant monotherapy was the most common form of treatment for bipolar disorder in Scotland and prescribing of lithium has declined between 2009 and 2016. The findings are concerning and represent a gap between treatment guidelines and clinical practice.Declaration of interestNone.
BACKGROUND: People with bipolar disorder typically require long-term pharmacological treatment to prevent episodes of depression or mania. However, evidence-based guidelines are often not followed by prescribers and, in some countries, prescribing of lithium is in decline. Polypharmacy is also common in bipolar disorder.AimsTo employ a data linkage approach to describe and evaluate prescribing patterns in bipolar disorder in Scotland between 2009 and 2016. METHOD: By linking prescribing data to the electronic Scottish Morbidity Records, we identified a cohort of 23 135 patients with bipolar disorder who were prescribed psychotropic medication between 2009 and 2016. We examined trends in proportions of patients prescribed each of six drug categories. Random effects logistic models examined change in prescribing over years of interest. RESULTS: The most common form of treatment was antidepressant monotherapy (24.96%), with only 5.90% of patients receiving lithium monotherapy. Prescribing of antipsychotics and anti-epileptics increased from 2009 to 2016 (antipsychotics: odds ratio 1.16, 95% CI 1.15-1.18; anti-epileptics: odds ratio 1.34, 95% CI 1.32-1.36), whereas prescribing of lithium decreased (odds ratio 0.83, 95% CI 0.82-0.85). Prescribing of valproate decreased from 2009-2016 in women, but increased in men (women: odds ratio 0.93, 95% CI 0.90-0.97; men: odds ratio 1.11, 95% CI 1.04-1.18). CONCLUSIONS: Antidepressant monotherapy was the most common form of treatment for bipolar disorder in Scotland and prescribing of lithium has declined between 2009 and 2016. The findings are concerning and represent a gap between treatment guidelines and clinical practice.Declaration of interestNone.
Authors: K N Fountoulakis; E Vieta; J Sanchez-Moreno; S G Kaprinis; J M Goikolea; G S Kaprinis Journal: J Affect Disord Date: 2005-05 Impact factor: 4.839
Authors: Viktoriya L Nikolova; Keerati Pattanaseri; Diego Hidalgo-Mazzei; David Taylor; Allan H Young Journal: J Psychopharmacol Date: 2018-03-19 Impact factor: 4.153
Authors: Alexander Viktorin; Paul Lichtenstein; Michael E Thase; Henrik Larsson; Cecilia Lundholm; Patrik K E Magnusson; Mikael Landén Journal: Am J Psychiatry Date: 2014-10 Impact factor: 18.112
Authors: Lars Vedel Kessing; Thomas Alexander Gerds; Bo Feldt-Rasmussen; Per Kragh Andersen; Rasmus W Licht Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: Daniel J Martin; Zia Ul-Haq; Barbara I Nicholl; Breda Cullen; Jonathan Evans; Jason M R Gill; Beverly Roberts; John Gallacher; Daniel Mackay; Andrew McIntosh; Matthew Hotopf; Nick Craddock; Ian J Deary; Jill P Pell; Daniel J Smith Journal: Br J Psychiatry Date: 2016-01-21 Impact factor: 9.319
Authors: Amanda M Lambert; Helen M Parretti; Emma Pearce; Malcolm J Price; Mark Riley; Ronan Ryan; Natalie Tyldesley-Marshall; Tuba Saygın Avşar; Gemma Matthewman; Alexandra Lee; Khaled Ahmed; Maria Lisa Odland; Christoph U Correll; Marco Solmi; Tom Marshall Journal: PLoS Med Date: 2022-04-19 Impact factor: 11.613